I-Mab (IMAB) Stock Price, News & Analysis

Company Overview

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Key Stats

• Today's Range: $2.39 to $2.59
• 50-Day Range: $0.81 to $2.80
• 52-Week Range: $0.60 to $3.08
• Volume: 354,719 shs
• Average Volume: 363,427 shs
• Market Capitalization: $200.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Buy

I-Mab Stock Analysis - MarketRank™

I-Mab scored higher than 52% of companies evaluated by MarketBeat, and ranked 479th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

I-Mab has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

I-Mab has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for I-Mab are expected to decrease in the coming year, from ($0.56) to ($1.35) per share.

Price to Book Value per Share Ratio

I-Mab has a P/B Ratio of 1.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.43% of the float of I-Mab has been sold short.

Short Interest Ratio / Days to Cover

I-Mab has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in I-Mab has recently decreased by 4.50%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

I-Mab does not currently pay a dividend.

Dividend Growth

I-Mab does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.43% of the float of I-Mab has been sold short.

Short Interest Ratio / Days to Cover

I-Mab has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in I-Mab has recently decreased by 4.50%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

9 people have searched for IMAB on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, I-Mab insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.10% of the stock of I-Mab is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 38.38% of the stock of I-Mab is held by institutions.

IMAB Stock Analysis - Frequently Asked Questions

How have IMAB shares performed this year?

I-Mab's stock was trading at $0.85 at the start of the year. Since then, IMAB shares have increased by 189.4% and is now trading at $2.46.
View the best growth stocks for 2025 here.

When did I-Mab IPO?

I-Mab (IMAB) raised $100 million in an initial public offering (IPO) on Thursday, January 16th 2020. The company issued 7,400,000 shares at a price of $12.00-$15.00 per share. Jefferies and CICC served as the underwriters for the IPO and China Renaissance and Huatai Securities (USA) were co-managers.

Who are I-Mab's major shareholders?

I-Mab's top institutional investors include Stonepine Capital Management LLC (0.59%), Ground Swell Capital LLC (0.08%) and HBK Sorce Advisory LLC (0.06%).

How do I buy shares of I-Mab?

Shares of IMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of I-Mab own?

Based on aggregate information from My MarketBeat watchlists, some other companies that I-Mab investors own include NVIDIA (NVDA), Tesla (TSLA), CrowdStrike (CRWD), NIO (NIO), Plug Power (PLUG), HubSpot (HUBS) and Intel (INTC).

Company Calendar

• Today: 6/23/2025
• Next Earnings (Estimated): 8/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMAB
• CIK: 1778016
• Web: www.i-mabbiopharma.com
• Phone: 86-21-6057-8000
• Fax: N/A
• Employees: 380
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.50
• High Stock Price Target: $7.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +124.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.23 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -19.81%
• Return on Assets: -18.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 22.35
• Quick Ratio: 22.35

Sales & Book Value

• Annual Sales: $3.89 million
• Price / Sales: 51.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.47 per share
• Price / Book: 0.99

Miscellaneous

• Outstanding Shares: 81,660,000
• Free Float: 63,613,000
• Market Cap: $200.07 million
• Optionable: Optionable
• Beta: 1.17